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Abstract
Laser interstitial thermal therapy (LITT) has emerged as a potential tool in the armamen‐
tarium of neurosurgeons managing patients with deep-seated and difficult-to-access
brain tumors. Advances in stereotactic neurosurgery coupled with neuroimaging tools
have led to the resurgence of interest in laser therapy for a variety of neurosurgical
indications.  Stereotactic  placement of  laser  probe using minimally invasive techni‐
ques and the ability to monitor the tissue ablation in real time using MR thermometry
are two distinct advantages of LITT. Patients with recurrent gliobastoma multiforme
(GBM) or newly diagnosed gliomas with significant medical comorbidities, radiation
necrosis,  radiosurgery-resistant  brain  metastasis  and  cancer-related  pain  pose
significant challenges in the field of neuro-oncology. LITT offers an opportunity to
obtain stereotactic biopsy and cytoreduction in a minimally invasive nature. In this
chapter,  we  have  described  the  current  applications  of  LITT  in  neuro-oncology,
including malignant gliomas, brain metastatic disease, radiation necrosis and other
indications  such  as  cancer-related  pain  and epilepsy.  We have  also  described the
principles,  technical  nuances  and  LITT  systems  currently  available  in  the  clinical
practice. With growing interest and acceptance of LITT in neuro-oncology, we are likely
to obtain high-quality evidence supporting the utility of this modality in patients with
a variety of neuro-oncological conditions in the near future.
Keywords: laser therapy, thermal therapy, gliomas, radiation necrosis, brain metasta‐
sis, epilepsy, cancer pain
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1. Introduction
Laser interstitial thermal therapy (LITT) has established itself as a new treatment modality in
neurosurgery due to its minimally invasiveness nature, safety and efficacy. Nowadays, LITT
has become a reality in the world of neuro-oncology [1–4], epilepsy surgery [5–7], and is also
emerging as an attractive option in the fields of spine surgery [8–10] and chronic pain syn‐
dromes[10–12]. In neuro-oncology, LITT has emerged as an option for malignant gliomas,
refractory brain metastatic disease and radiation necrosis. LITT is best suited, but not limited,
for patients with tumors located in deep-seated, difficult-to-access areas that could develop
significant postoperative neurological deficits and poor performance status with traditional
microsurgical resection. It is a FDA-approved treatment option for intracranial lesions includ‐
ing recurrent glioblastomas [4]. Concerning brain metastatic disease, although stereotactic
radiosurgery (SRS) has become the standard of care for most patients, the failure rate associat‐
ed with SRS is up to 23% [13–15]. Additionally, the potential risk of developing radiation necrosis
following SRS can vary from 1.4 to 24% [16–18], and this complication can be refractory to
standard therapeutic options like steroids and Bevacizumab. LITT has been effective in managing
both radiosurgery-resistant brain metastasis [2, 3, 19–22] and radiation necrosis [3, 21–24].
The surgical applications of lasers are represented by three distinct functionalities of this
technology: photocoagulation, photovaporization and photosensitization [25]. LITT is referred
to the first one, photocoagulation, which implies tissue damage by thermal energy provided
by a source of constant and continuous laser delivery to a planned target volume. It was first
introduced in 1983 by Bown and colleagues [26], who used a neodymium-doped yttrium
aluminum garnet (Nd:YAG) laser and achieved focal tissue coagulation in an experimental
brain tumor model without tissue vaporization. Research using experimental animal models
demonstrated the brain tissue changes in response to hyperthermia and confirmed that
coagulation necrosis could result from the application of thermal energy to brain tissue [27–
30]. However, the inability to monitor and control the laser-induced thermal effects limited
the widespread application of this technology. Recent advances in magnetic resonance (MR)
thermography [31] allowed real-time image feedback of laser thermal energy delivery, making
it possible to predict the thermal damage of a planned target in the brain.
In the present chapter, the authors describe the current applications of LITT in neuro-oncolo‐
gy, including malignant gliomas, brain metastatic disease and radiation necrosis together with
the basic principles and technical nuances related to the surgical procedure and the current
LITT systems available in clinical practice. We also touched upon other applications of LITT
such as cancer-related refractory pain and epilepsy. Future directions are also discussed in this
chapter.
2. Laser interstitial thermal therapy: principles and rationale
Treating cancers with heat energy dates back to 1960s when Rosomoff et al. [32] first report‐
ed the application of ruby pulsed laser beam in two patients with GBM and in experimental
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animals. They reported that in normal brains of experimental animals, laser application was
associated with total cellular destruction with vacuolization secondary to vaporization and
hemorrhage. The sensitivity to laser can be increased by Cardio-green and Evans blue
injections. Whereas on brain tumors in patients with GBM, laser therapy induced cellular
necrosis without hemorrhage and inflammation. Laser bursts were given at 2 min interval at
estimated 3 cm depth from the cortical surface, followed by progressive 1 cm depth till
approximately 9 cm depth from the surface was reached. Differential susceptibility of normal
and tumor to laser application was noted in this study. However, given that the precise
application and delivery of laser energy were not feasible at that time, this therapy has fallen
out of favor and did not get acceptance in routine clinical practice. In 1985, Winter et al. [33]
used microwave hyperthermia for treating brain tumors. Later, brain tumors were treated with
focused ultrasound by Britt and coworkers [34]. Following these reports, another study [35]
investigated the use of interstitial hyperthermia and iridium brachytherapy in malignant
gliomas.
Without the availability of technology to safely monitor the extent of hyperthermia, these
techniques remained largely experimental and were unable to be integrated in mainstream
clinical practice. When the technological advancements overcome these limitations, thermal
ablation using LITT was considered as a more viable, practical and cost-effective approach in
treating brain tumors in selected patients. Using LITT, otherwise surgically inaccessible tumors
were made amenable to surgical ablation with good outcomes [36, 37]. Though earlier
generation probes like Nd-YAG lasers had limitations such as charring of adjacent tissue, thus
limiting energy penetration and uncertainties in the extent of tissue ablation [37, 38], new-
generation probes have protective mechanisms to prevent charring and also use real-time MR
imaging (MR thermometry) to monitor the extent of ablation for minimizing thermal dam‐
age to normal surrounding brain parenchyma.
3. Histopathological and biological effects of LITT
Delivering thermal injury with LITT causes some major biological changes in the tissues [39].
Laser photons in the near-infrared range, when directed to the target tissue, get absorbed and
converted to heat energy. Aided by abundant blood flow, conduction, convection and
refraction all play a significant role in distributing the heat energy around the target tissue [39].
The inherent biology of the surrounding structures and the physical properties of the laser
determine the uniformity in the distribution of the heat applied. Ablation of the entire target
lesion is the primary aim of using LITT [40].
Cellular homeostasis is usually not disturbed with mild elevation in temperature to approxi‐
mately 40°C. However, when the temperature is increased in the range of 42 to 45°C (hyper‐
thermia), there is a substantial increase in susceptibility to cellular damage [40, 41]. When the
temperature is increased from 46 to 60°C, marked cytotoxicity and cell death ensue with
considerably decreased time needed to kill the cells [42, 43]. Above 60°C, there is substantial
damage to the mitochondrial enzymes, cytosol and the nucleic acid proteins that culminate to
coagulation necrosis [44]. Super boiling temperatures like 105°C results in charring, tissue
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boiling, vaporization, and carbonization which if not released immediately might culminate
in increased intracranial pressure. Apart from the true values of the temperature used, the time
of exposure to such temperatures is also important. For example, 43°C for 2 min causes
reversible damage to the tissue, while the same temperature for 10 min causes permanent tissue
damage and for 60 min causes coagulative necrosis [22, 45]. Based upon the Arrhenius
equation, only shorter intervals are needed when using high temperatures to get the same
results [46].
The target lesion usually undergoes central coagulation necrosis following LITT therapy,
surrounded by a zone of edema next to the undamaged tissue [36]. By the end of 1st week,
granulation tissue gradually replaces the zone of necrosis. The targeted lesion then develops
into a cystic lesion with remnant necrotic debris surrounded by reactive gliosis with mesen‐
chymal deposits [47, 48].
Three distinct zones can be identified on MRI following LITT. The first central zone repre‐
sents the zone of coagulation necrosis and if the temperature inadvertently exceeds 100°C, then
there is a chance of charring and vaporization followed by a pseudo cavity formation. Just
outside the core area lays a non-viable part with increased interstitial fluid called the inter‐
mediate zone. The outermost marginal zone is viable consisting of edematous viable sur‐
rounding brain parenchyma following thermal exposure and sharply delineates itself from the
inner two zones. The ultra-structure of the inner two zones of thermal injury show disrupt‐
ed organelles and evidence of apoptosis, whereas the outer zone shows only axonal swelling,
neuronal shrinkage and hypertrophied endothelial cells with no evidence of vessel thrombo‐
sis [4, 49–51]. Following LITT therapy, the target lesions might exhibit an increase in size due
to necrosis and perilesional edema, but eventually will shrink and form a rim of granulation
tissue.
4. Technical aspects and commercially available components of LITT
4.1. MR thermometry
After numerous attempts of measuring the thermal energy delivery to the target tissue during
LITT, including the use of skin thermometers, subcutaneous and interstitial probes, infrared
detectors and thermographic cameras [28, 29, 52–56], it was the addition of MR thermometer
that played the most significant role in allowing real-time monitoring and quantification of
thermal energy delivery leading to thermal ablation [27]. MR thermography based on the
temperature-dependent water proton resonance frequency (PRF) is capable of providing
visual imaging together with a quantification model of thermal deposition with accurate
temporal and spatial resolution. The theory behind PRF is based on the fact that as tempera‐
ture increases during LITT, the number of free H2O molecules also increases due to break‐
age of hydrogen bonds between H2O molecules. The hydrogen nuclei (proton) are mobilized
more efficiently within the gradient field when in the free H2O molecule state, producing real-
time imaging that can be interpreted and visualized using the proper computer software in
the treatment workstation [57, 58].
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4.2. Lasers and probes used for LITT
The two most common types of lasers used for LITT are the continuous-wave neodymium-
doped yttrium aluminum garnet (Nd:YAG), with a wavelength of 1064 nm, and diode lasers
with wavelengths between 800–980 nm, which operate at a wide range of powers [1, 59, 60].
Nd:YAG lasers are capable to achieve deeper tissue penetration compared to diode lasers,
especially in soft tissues with high blood perfusion at wavelengths between 1000–1100 nm [59,
61]. Diode lasers have the advantage of producing lesions faster, but typically with less
penetration [2].
LITT probes have three main components: an optical fiber with a 600 μm diameter, a heat-
resistant terminal tip made of sapphire or quartz, measuring around 10 mm [59] and a cooling
system, which is required to avoid overheating, tissue carbonization and optical fiber
damage [61]. The current cooling mechanisms use either a cooled gas system (CO2) or a
constant stream of fluid (water or saline) delivered to the tip of the probe through a sheath
associated to the optic fiber [60, 62]. The thermal energy delivery at the probe tip has been
classically described as a symmetrical ellipsoid shape centered along the axis of the probe.
Recent advances in probe design, most specifically by the NeuroBlate® System (Monteris
Medical Corporation, Plymouth, MN, USA), also led to the development of side firing laser
probes, which allows the surgeon to control the laser ablation of complex shaped tumors in a
real-time fashion.
4.3. Commercially available LITT systems used in neurosurgery
Currently, there are two commercially available FDA-cleared LITT systems for neurosur‐
gery in the United States: the NeuroBlate® System (Monteris Medical Corporation, Plymouth,
MN, USA) and the Visualase Thermal Therapy System (Medtronic Inc., Minneapolis, MN,
USA).
The Visualase Thermal Therapy System uses a 15 W 980 nm diode laser generator that supplies
energy to a disposable 1.65-mm diameter outer cooling catheter, which contains a 1cm-long
fiber optic with a light diffusing, tip [2, 63]. The cooling mechanism is provided by circulat‐
ing sterile saline [2] and limits the duration of laser application to several minutes. Thermal
energy is delivered in an ellipsoid-cylindrical fashion. The system is a MRI-guided laser
ablation system, which is connected to a computer workstation capable of displaying real-time
thermography data at the target location. Thermal information produces color-coded
“thermal” and “damage” images [3, 27]. Limit temperatures can be designated as safety points
on the pre-treatment MRI such that if during treatment an increase in temperature beyond the
designated limit is detected at those points, the laser is automatically deactivated.
The NeuroBlate® system consists of a solid-state Dornier diode laser operating at the Nd:YAG
wavelength (1064 nm) with a laser output of 30 W. The probes are available at diameters of 3.2
and 2.2 mm. The cooling mechanism is provided by a CO2 gas-cooled system [22, 45]. One
unique feature of this system is that both side-firing and diffuse-tip probes are available. The
NeuroBlate® directional side-firing laser probe is aimed for contoured ablation of complex
shaped targets while the diffusing-tip laser probe is designed to provide fast volumetric
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ablation in a concentric fashion. The probes are inserted using frameless stereotactic guid‐
ance. The Monteris® Mini-Bolt provides rigid skull fixation and allows a direct interface to the
NeuroBlate laser probe. The system is a MRI-guided laser ablation system, which is connect‐
ed to a computer workstation capable of displaying real-time thermography data at the target
location. The NeuroBlate software displays the extent of thermal energy delivered as ther‐
mal-damage-threshold (TDT) lines. The yellow line surrounds the target volume that has
received the thermal energy equivalent of 43°C for at least 2 min; the blue line surrounds the
target volume that has been exposed to 43°C for at least 10 min; finally, the white line
corresponds to tissue exposed to 43°C for 60 min. Tissues located outside the yellow TDT line
are expected to have no permanent damage, while tissue volume inside the blue line under‐
goes severe thermal damage and tissue volume within the white line experiences coagula‐
tion necrosis [22, 45] (Figure 1).
Figure 1. (a–d) show the individual components of NeuroBlate® System including the bolts (b), laser probes (c) and
robotic motor drive (d). Figures 1e–f depict the integration of robotic motor drive with the MRI scanner. (Images used by
permission from Monteris Medical Corporation, Plymouth, MN, USA. The use of any Monteris Medical photo or image does not
imply Monteris’ review or endorsement of any article or publication).
Disclosures: Drs. Gene Barnett and Alireza Mohammadi are consultants of Monteris Medical
Company (NeuroBlate System). Figure 1 is provided by Monteris Medical Company and is
the only contribution of this company in this chapter.
5. Animal models and preclinical studies
Various canine [32, 64, 65] and murine [48, 66–68] animal models of brain tumors have been
used to investigate the efficacy of laser thermal therapy on tumors and surrounding brain
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tissue, as well as to evaluate the thermal dose models. First, animal experiments evaluating
the impact of laser energy on normal murine brains can be dated back to 1960s. Fine et al. [68]
used ruby pulsed laser delivering 100 J of energy to the forehead of mice, which resulted in a
mortality rate of 75% within a day of exposure. Later, Earle et al. [67] showed that 20–40 J of
energy delivered using ruby laser was not lethal and resulted in sub-arachnoid and intracere‐
bral hemorrhage with minimal neurological effects. Later, Rosomoff et al. [32] reported similar
findings using 8 J ruby laser in a rat and dog experiment models. They also reported that the
sensitivity to laser could be increased by Cardio-green and Evans blue injections. Kangasnie‐
mi et al. [64] reported the feasibility and utility of MR-guided laser (980 nm diode) ablation of
tumors (transmissible venereal tumors) in seven canines. Utility of LITT was studied in Lewis
mice implanted with glioma cells [48] and neoplastic lesion was monitored using MRI. In
addition, proliferation of implanted tumor cells, gliosis and apoptosis was monitored using
immunohistological techniques. LITT caused necrosis of neoplastic cells; however, apoptosis
of residual tumor cells at the margin (more vascularized compared to pre-treatment) was noted
following LITT [48]. Canine models have also been used to establish various thermal dose
models, so as to reliably predict post-LITT tissue damage as well as to monitor tissue abla‐
tion in real time [65]. Localized interstitial thermal therapy using magnetic nanoparticles
(dextran- or aminosilane-coated iron-oxide nanoparticles) have been described in a rat model
of GBM [69]. Interestingly, rats treated with aminosilane-coated nanoparticles showed
improvement in survival (4.5 times prolongation), whereas those treated with dextran-coated
particles did not show any difference in survival compared to controls. These animal experi‐
ments paved a way to the development of LITT and future therapeutic options for gliomas.
6. Use of LITT in gliomas
High-grade glioma or glioblastoma multiforme (GBM, WHO grade IV), in particular, is a
significant clinical challenge in the field of neuro-oncology with a high rate of morbidity and
mortality. GBM constitutes approximately 45% of all malignant primary glial neoplasms [70].
Gross total surgical resection with concurrent chemo-radiotherapy is the mainstay treatment
modality for this aggressive tumor [71]. However, even with the best available treatment
options, 5-year overall survival (OS), progression-free survival (PFS) and median survival
have been reported to be 9.9%, 6.9 months and 14.6 months, respectively [59, 71, 72]. The
median survival decreases to 12.1 months with post-resection radiotherapy alone instead of
concurrent chemo-radiotherapy and to 6.2 months in patients with progressive disease
following standard treatment regimen [71, 72]. There is controversial data regarding optimal
management (surgical vs. medical) in patients with recurrent GBM. Extent of resection greater
than 80% has been shown to have improved overall survival in carefully selected patients with
recurrent GBM [73–75]. Young patients with good performance status have been shown to
have improved overall survival following surgical resection for recurrent GBM [76, 77];
however, after adjusting for age, no significant benefit was achieved following repeat
surgery [77]. In addition, redo craniotomy for progressive GBM is associated with increased
risk of per-operative complications including neurological deficits (18–22%) [78, 79]. Also,
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there is a cumulative risk of these complications following each craniotomy with maximum
risk between first and second procedures [80]. There is insufficient evidence supporting the
role of radiosurgery, stereotactic fractionated radiation therapy or interstitial brachytherapy
in patients with recurrent GBM [81, 82]. Of note, radiosurgery has also been shown to be
associated with increased toxicity in patients with recurrent disease [81]. Survival benefit of
9.3 months have been reported in patients (good performance status) receiving interstitial
brachytherapy for recurrent GBM [82]. Given a high incidence of this primary brain tumor
with lack of effective therapies and dismal outcome, significant research is directed toward
developing effective medical and surgical treatment modalities to improve overall and
progression free survival. Laser interstitial thermal therapy (LITT) is one of the advance‐
ments in the surgical management of these tumors. LITT is a minimally invasive procedure,
which involves stereotactic-guided placement of laser probe and utilizes thermal energy to
cause protein coagulation and cell death [83, 84]. Advances in neuroimaging coupled with
stereotactic techniques have led to the resurgence of interest in the utility of laser thermacoa‐
gulation in patients with brain tumors. In addition, integration of MR thermography to LITT
made it possible to deliver thermal energy under real-time monitoring, thus avoiding injury
to surrounding normal brain tissue [85]. Given these advantages of LITT, this technique has
been utilized for a variety of neurosurgical indications such as deep-seated gliomas [1, 4, 86,
87], epilepsy [20, 88], brain metastasis with radiation necrosis [19, 23, 24, 49] and cinguloto‐
my for intractable pain [12, 89].
First report of utilization of Nd-YAG laser thermal therapy in five patients with deep-seated
brain tumors was published in 1990 [90]. Later, several studies with a smaller (n < 8) sample
size reported the utility of this modality in patients with grade II/III gliomas [36, 87, 91–93].
In 2001, Leonardi et al. [94] reported the utility of stereotactic-guided laser-induced intersti‐
tial thermotherapy (SLITT) in 24 patients with residual/recurrent brain tumors [94]. Twenty-
four patients with primary glial tumors (17 high grade and 7 low grade gliomas) underwent
30 Nd-YAG laser (1064 nm) procedures under local anesthesia using 0.2T MRI guidance [94].
Interestingly, the tumor ablation was monitored using 3D turbo-FLASH T-1W MRI while laser
was applied in steps. Two different lesion architectures at 1108, 1393 J and tissue necrosis at
2979 J were observed on MR imaging during laser ablation. No correlation between the tissue
response to thermal treatment and the grade of the tumor was observed in this study [94]. Of
note, tumor response rate and clinical outcomes were not reported in this study [94].
Complications such as neurological deficits (n = 4), seizures (n = 2) and superficial wound
infection (n = 1) were reported following LITT in this study. A year later, same investigators
reported an overall survival of 34, 30 and 9 months in patients with low-grade astrocytoma,
anaplastic gliomas and GBM, respectively, following LITT in 24 patients with brain tumors.
Similarly, mean time to progression (PFS) for low-grade astrocytoma, anaplastic gliomas and
GBM was reported to be 16, 10 and 4 months, respectively, in this study [86]. In 2005,
Schwarzmaier et al. [95] reported MR-guided (0.5T) partial ablation using LITT in two patients
with recurrent GBM. One of these patients had multifocal GBM, which was found during
follow up of primary tumor and underwent LITT for the second focus, whereas second patient
had GBM recurrence after standard treatment. Survival of 16 and 20 months following GBM
recurrence was reported in this study, thus implicating the role of LITT in achieving im‐
Neurooncology - Newer Developments290
proved tumor control and overall survival [95]. A year later, same investigators reported the
results of MRgLITT in 16 patients with recurrent GBM with a mean follow up of 9.1 ± 6.3
months [1]. The mean tumor volume treated was 21.6±18.6 cm3, six patients had two proce‐
dures and three patients had three LITT procedures. Of these 16 patients, 15 had surgery, 16
had radiotherapy and 6 had chemotherapy prior to LITT and all patients received chemother‐
apy following LITT. Authors have reported median survival of 5.2 and 11.2 months after
recurrence in first the 10 and later 6 patients, respectively, with an overall median survival
of 9.4 months after recurrence and 6.9 months after LITT. Authors have attributed this
difference in median survival between the first (n = 10) and the later cohort (n = 6) of patients
to the “learning curve” in terms of delay between the tumor recurrence and LITT (2 months
vs. 0.3 months in first and later group) [1]. Neurological complications including transient
weakness in right upper limb in one patient and non-neurological complications such as
neutropenia (n = 3), thrombocytopenia (n = 1) and deranged liver function tests (n = 1) following
LITT was reported in this study [1]. Of note, the length of hospital stay was 12.0±4.2 days with
no ICU stay and 12 out of 16 patients were dead at the end of the study (7 deaths were due to
tumor progression and 5 deaths were due to pulmonary embolism, septic mycosis, gastro-
intestinal bleeding, sigmoid perforation with peritonitis). Carpentier et al. [96] reported utility
of MRgLITT (1.5 T) as a salvage therapy in four patients with recurrent GBM following
standard treatment regimen. Five recurrent tumors in four patients (two temporal, one corpus
callosum, one centrum semiovale and one temporal) with mean diameter of 16.4 mm under
total ablation using Visualase system in this study. All patients except one underwent complete
resection prior to salvage LITT. Recurrence was noted following a mean progression-free
survival of 37 days and mean overall survival of 10.5 months following LITT, which is longer
than the overall survival in patients with recurrent GBM (approximately 4–6 months) [71, 72].
Of note, local recurrence was noted in two patients (45, 30 and 19 days) and another two
patients (30 and 60 days) had distant recurrences following LITT. The procedure was well
tolerated in all patients with transient adverse effects such as single episode of seizure (n = 1),
supplementary motor syndrome (n = 1) and CSF leak (n = 1) [96]. In 2013, the first human phase
I study investigating the safety and efficacy of escalating dose of thermal energy using LITT
in patients with recurrent GBM was published [4]. This was a multicenter study and enrol‐
led 11 patients at two centers (Cleveland Clinic and UH-case Western Medical Center) from
September 2008 to October 2009. Inclusion criterion sued in this study was: adult patients with
recurrent GBM following standard treatment regimen, KPS≥ 60, tumor size 15–40 mm cross-
sectional dimension, supratentorial location of the tumor, stable medical comorbidities and no
concurrent adjunct therapies. Of note, the primary end point of the study was the safety and
feasibility of the NeuroBlate® system whereas the overall survival, progression-free survival,
improvement in KP score and change in tumor volumes were the secondary end points [4].
Three thermal dose threshold lines [TDT, yellow (43°C for 2 min), blue (43°C for 10 min) and
white lines (43°C for 60 min)] were chosen for the study based on previous animal studies. Ten
patients underwent LITT procedure and were followed up for a minimum of 6 months or until
death, which ever was earlier. All patients died secondary to disease progression following
LITT therapy with a median follow up of 8 months. Three patients were initially enrolled for
yellow thermal dose threshold line (43°C for 2 min) to the tumor margin. These three pa‐
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tients were followed for 14 days and assessed for any toxicity (defined as decrease of 20 or
more points on KPS score). If an independent committee in two out of three patients noted
toxicity, the thermal dose was either modified or the trial was halted. If there were no
consequences during the follow up of 14 days, another three patients were enrolled for blue
and white thermal dose threshold lines subsequently using the same protocol [4]. Mean total
and treated tumor volume in all treated patients were 6.8 ± 5 cm3 and 5± 3.2 cm3 (78% of total
tumor volume), respectively, in this study [4]. The procedure took approximately 2–8 mins/
slice and was well tolerated in all the patients with a median hospital stay of 3 days. One entry
site infection at 147 days following LITT was reported with no other significant procedure-
related complications. Adverse events such as dysphasia with upper limb weakness (n = 1),
homonymous hemianopia with contralateral weakness (n = 1), intracerebral hemorrhage due
to rupture of pseudo aneurysm (n = 1, 6 weeks after LITT and was managed by endovascu‐
lar coil placement), white matter injury with hemiparesis (n = 1), deep vein thrombosis (n = 3),
pulmonary embolism (n = 1) and grade 3 neutropenia (n = 1) were reported following LITT in
this study. Post-LITT edema was noted at 48 h MRI and was managed with steroids.
Interestingly, one patient with gliosarcoma developed tumor seeding along the biopsy tract
involving the skull and epicranial tissue 9 months after the LITT procedure [4]. The median
progression-free survival at 6 months and median overall survival were reported to be ≥ 30 %
(compared to 15% reported in the literature) and 316 days, respectively, following LITT in this
study. Two deaths were reported during the follow up and the authors concluded LITT to be
safe and effective (especially with blue and white TDT ablated zones) in carefully selected
patients with recurrent deep-seated GBMs. DTI tractography and angiography might improve
the safety profile of LITT, by delineating the critical neural and vascular structures along the
tract of laser probe [4]. Mohammadi et al. [97] investigated the efficacy of LITT in 34 patients
with high-grade gliomas HGG (GBM, n = 24 and anaplastic astrocytoma/oligodendroglioma,
n = 10) in difficult-to-access (DTA) areas in a multicenter retrospective study. Of these 34
patients, 16 patients (16 procedures) underwent LITT as an upfront therapy and 18 patients
(19 procedures) underwent LITT for recurrent disease. Median time from initial diagnosis of
HGG was 29 months for LITT therapy in patients with recurrent disease with a median follow
up of 7.2 months following LITT. Following LITT, all patients had standard adjunct treat‐
ment and were monitored with serial follow-up MRIs every 3 months. Progression-free
survival was the primary end point, whereas overall survival and complications were
considered as secondary end points in this study. Frontal lobe was the most common
location (n = 15), followed by thalamus (n = 7), parietal and temporal (n = 5 each) and corpus
callosum in a single patient. The median tumor volume that was treated using LITT was 10.13
cm3 and 3 cm was the maximum tumor diameter in this study [97]. And, 98% of tumor volume
was covered with yellow TDT lines and 91% with blue TDT lines, with median hospital stay
of 3 days. Progression-free survival during the median follow up of 7.2 months was 5.1 months
and 71% of treated patients had progressive disease. Majority (52%) of tumor progression
following LITT was noted at the periphery of tumor, followed by at the center of the ablated
zone (22%), outside the treatment field (22%) and in the contralateral hemisphere (4%). One
year estimated survival was 68± 9 % and 12 patients (35%) expired due to disease progres‐
sion during the follow up. Based on the volume of tumor covered by yellow and blue TDT
Neurooncology - Newer Developments292
lines, patients were stratified as favorable (<0.05 cm3 tumor volume missed by yellow TDT
lines and <1.5 cm3 of tumor volume between yellow and blue TDT lines) and unfavorable
groups (≥0.05 cm3 tumor volume missed by yellow TDT lines and ≥1.5 cm3 of tumor volume
between yellow and blue TDT lines) [97]. The median PFS in favorable group was 9.7 months,
whereas it was 4.6 months in unfavorable group. Interestingly, when controlled for tumor
volume of >10 cc, the effect of TDT line coverage on PFS did not reach significance in this study.
In terms of adverse events, 13 adverse events (37%) were noted in this study. Transient (n = 5)
and permanent (n = 2) worsening of preoperative neurological deficits, superficial infection
(n = 1), deep vein thrombosis (n = 1), ventriculitis (n = 1), seizure (n = 1), hyponatremia (n = 1),
hydrocephalus (n = 1), intracerebral hematoma (n = 3) and mortality due to intracerebral
hematoma (n = 1) were the complications following LITT noted in this study [97]. This study
showed LITT to be an efficacious therapy in patients with primary or recurrent high-grade
gliomas in difficult to access areas. However, major limitations of this study were its retro‐
spective nature and small sample size. A recent single center retrospective study reported the
utility of LITT in patients with a variety of intracranial pathologies including gliomas (n = 34)
[98]. Total operative time and ablation time were 2.9±0.6 hrs and 9.3±6.5 mins, respectively.
Median ICU and hospital stay was 1.0 day each and average hospital stay was 3.6±5.4 days
following LITT in this study. There was an overall increase in size of lesion immediately
following LITT, followed by a gradual reduction in size 24 h after the procedure which was
similar to that at first follow up [98]. Postoperative complications such as neurological
worsening (n = 7), hemorrhage (n = 2), edema (n = 4), infection (n = 1), inaccurate catheter
placement (n = 2) and deaths (n = 2) were reported [98]. Mortality occurred in two patients with
glioblastoma multiforme (midbrain/pons in one patient) who developed malignant cerebral
edema following LITT. One patient underwent hemicraniectomy with no successful out‐
come and died in the same admission. The 30-day readmission rate was 5.6% in this study. Of
note, outcome measures such as overall survival, progression-free survival or recurrence were
not reported in this study [98].
Although there is no Class 1 evidence supporting the efficacy of LITT in patients with high-
grade gliomas, there is also paucity of high-quality data supporting the role of craniotomy and
surgical resection in such patients [99]. Given the minimally invasive nature of LITT coupled
with advances in neuroimaging stereotactic techniques and thermography, LITT can be a
useful treatment modality in patients with poor performance status or medical comorbidi‐
ties and high-grade glioma. The advantages of LITT have led to the exploration of this
technique for a variety of intracranial tumors. LITT has been investigated in various prospec‐
tive case-controlled studies and there is a likelihood to have Class 2 evidence data in the next
couple of years.
7. Use of LITT in brain metastasis and radiation necrosis
Brain metastasis is a common and challenging clinical scenario affecting up to 40% of patients
with systemic malignancies [100–102]. Lung carcinoma (16–19%) is the leading systemic cause
of brain metastasis followed by renal (6–9%), melanoma (7–7.4%), breast (5%) and colorectal
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cancers (1.2–1.8%) [103, 104]. Prognosis in patients with brain metastasis is often dismal, due
to limited therapeutic options. Majority of chemotherapeutic agents and targeted immuno‐
therapies do not cross the blood brain barrier, hence limited applicability of these agents in
management of patients with brain metastasis. Stereotactic radiosurgery (SRS) has emerged
as a primary therapeutic modality in patients with single or multiple brain metastases with an
improvement in overall survival and quality of life [13, 14, 105, 106]. However, there is a subset
of patients (up to 23%) who fail SRS with progression of metastatic disease and subsequent
mortality [13, 15]. Brain metastasis from radio-resistant systemic tumors such as renal cell
carcinoma, sarcoma, melanoma and triple negative breast carcinoma carries a worse progno‐
sis, despite better control rates with SRS as compared to conventional radiotherapy [107].
Stereotactic radiosurgery is also associated with adverse radiation effects (AREs) with a 1-year
cumulative incidence of 13–14%, which increases with size and volume of the tumor [108–111].
Of these adverse radiation effects, radiation necrosis (RN) is the most challenging in terms of
diagnosis and management with a reported incidence ranging between 1.4% and 25% [16–18,
112]. Imaging modalities such as MR perfusion, MR spectroscopy, 6-[(18)F]-fluoro-L-3,4-
dihydroxyphenylalanine (F-DOPA)/FDG PET, l-methyl-(11)C-methionine ((11)C-MET) and
SPECT scan have been shown to be useful in differentiating radiation necrosis from recur‐
rent metastasis or tumor [113–116]. The sensitivity, specificity, accuracy of perfusion MRI and
F-DOPA PET have been reported to be 86.7, 68.2, 75.6 and 90, 92.3, 91.3%, respectively [114].
SPECT scan has been shown to have the highest specificity of 97.8% (sensitivity 87.6%) for
differentiating tumor progression and radiation necrosis and may be preferred over other
imaging modalities [116]. Medical therapeutic options for RN include corticosteroids,
Bevacizumab, hyperbaric oxygen therapy, anticoagulation (heparin or warfarin) or vitamin
E [117–125]. Surgical resection of RN can be considered in symptomatic patients with mass
effect in accessible areas [125]. Therefore, there is always a scope for newer treatment strat‐
egies in the management of patients with brain metastasis to improve the clinical outcomes.
LITT is a minimally invasive technique that offers an alternative therapeutic option in patients
with either SRS-failed or radio-resistant brain metastasis. LITT also offers an opportunity to
have a histological diagnosis before laser ablation in cases of suspicion between recurrence of
metastasis and radiation-related changes. The minimally invasive nature of this technology
permits its utility in patients with multiple medical comorbidities with poor Karnofsky
performance status (KPS) and tumors in difficult-to-access locations.
First use of laser therapy for brain metastasis was reported in 1986, with successful-laser
assisted ablation of a midbrain metastasis from primary lung adenocarcinoma [126]. In 1990,
Sugiyama et al. [90] reported the utility of laser in patients with deep-seated tumors includ‐
ing metastasis. Later, Schulze et al. [36] studied the histological effects of laser thermothera‐
py in seven patients with brain metastasis and eight patients with glial tumors. In this study,
authors reported that laser therapy created a unique pattern of architectural changes at the
histological level with central zone of necrosis surrounded by edematous tissue. This sur‐
rounding edematous tissue tends to undergo cystic changes following regenerative and
resorptive changes [36]. In addition to thermal coagulation, laser-induced tumor damage is
caused by disruption of cellular membranes and organelles. Authors advocated this techni‐
que in older patients with significant medical comorbidities and brain tumors. First pilot
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clinical trial investigating the safety and feasibility of LITT in patients with resistant focal
metastatic brain tumors was reported in 2008 [2]. Four patients with six metastatic brain
tumors (temporal lobe, n = 2; parietal lobe, n = 2; frontal lobe, n = 1; and occipital lobe, n = 1)
were enrolled in this trial. Follow-up MRI scans were performed at 7, 15, 30 and 90 days after
the procedure to monitor the zone of thermal necrosis. LITT was well tolerated and all patients
were discharged within 14 h after the procedure in this study [2]. There was an acute in‐
crease in the tumor volume immediately after the procedure followed by a gradual reduc‐
tion in the volume during the follow-up imaging. No adverse events, complications or tumor
recurrence within the ablated zones were noted during the follow up [2]. Results of this trial
were published in 2011, which showed no tumor recurrence in ablated zones in all 7 patients
(15 metastatic tumors) at a follow up of 30 months [19]. Mean age of patients enrolled in this
study was 54 years, with breast or pulmonary adenocarcinoma and average number of
metastasis per patient was 3.3. Total coverage of the tumor under TDT lines was achieved in
nine patients and partial coverage in six patients. Single applicator for laser delivery was used
in majority of patients (n = 13) and two applicators in another two due to complex tumor shape.
Majority of tumors were less than 2 cm in size (n = 10) and another five were 2–3 cm in size.
Mean duration of the procedure and hospital stay was 135 mins and 26 h, respectively, and all
patients were discharged within 24 h of procedure [19]. Complications such as blood suffu‐
sion, probe misplacement, transient aphasia and cerebellar syndrome were reported follow‐
ing LITT therapy. Of note, there was a mean increase of 26% (range 0–124%) in tumor volume
at a mean interval of 4.7 days (range 0–15 days) after the procedure, which returned to baseline
volume within 20 days (range 0–75 days). Following LITT, contrast-enhancing rim of the
metastasis disappeared in a mean interval of 12.2 months. Mean overall survival and progres‐
sion-free survival following LITT were 17.4±3.5 months and 3.8±1.0 months, respectively [19].
Another study reported progression-free and overall median survival of 5.8 months each
following LITT in five patients with metastasis (non-small cell lung carcinoma, n = 2; colon
adenocarcinoma, n = 1, melanoma, n = 1, fallopian tube carcinoma, n = 1) [20]. Frontal lobe was
involved in two patients, fronto-parietal in one, insula in one and parietal in one patient. Four
patients had one trajectory and another two patients had double trajectories for laser thera‐
py. Of note, mean hospital and ICU stay following LITT were 4.4 days and 1 day, respective‐
ly, in patients with metastasis [20]. This duration of hospital stay following LITT was
significantly higher as compared to previous study by Carpentier et al. [19, 20]. Complica‐
tions such as transient aphasia (insula) and hemiparesis (frontal) were noted following LITT,
which improved gradually with steroids. Patient with melanoma metastasis showed stable
tumor size with edema and decrease in size of lesion at 1 and 3 months, respectively, follow‐
ing LITT on follow-up MRI [20]. Two patients had systemic progression; other two had CNS
progression and none of the patients required additional treatment in this study.
Torres-Reveron et al. [3] reported the utility of LITT in six patients with progressive brain
metastatic tumors (non-small cell lung cancer, n = 2; melanoma, n = 2; small cell lung cancer,
n = 1; ovarian cancer, n = 1) following SRS. Tumor recurrence was diagnosed using PET and
SPECT imaging in two patients, each using these imaging modalities; however interestingly,
stereotactic biopsy prior to ablation therapy was negative in all the patients [3]. There was an
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increase in length (63%) and width (64%) of the tumor on post-operative MRI at 2 weeks after
LITT compared to preoperative size similar to previous studies [19, 20, 24]. However, in
concordance with previous studies, tumor size returned to baseline within 4.5 to 6 months
following the procedure in all the patients [3]. Interestingly, initial increase in size of lesion
was not associated with increase in concurrent FLAIR signal changes on post-operative MRI
at 2 weeks after the procedure. These radiological changes were also associated with improve‐
ment in clinical symptoms and thus the ability to wean off the patient from steroids.
Satisfactory tumor control was achieved in four out of six patients; one patient had progres‐
sion of systemic disease and died within 1 month of procedure. Another patient had progres‐
sive increase in tumor size 3 months after the procedure following initial response, and surgical
resection of the tumor showed tumor progression. No significant complications were reported
in this study. Similarly, another study investigated the efficacy of LITT in recurrent lesions
following stereotactic radiosurgery for brain metastasis [21]. Of note, biopsy and histological
diagnosis was not routinely performed in this study and authors advocated LITT irrespec‐
tive of clinical diagnosis (tumor recurrence vs. radiation necrosis). Seventeen LITT proce‐
dures were performed in 16 patients and 14 patients (15 procedures) were available for follow
up in this study. Non-small cell lung carcinoma (n = 12) was the most common systemic
malignancy metastasizing to the brain, followed by breast and colon adenocarcinoma. Average
time interval between SRS and LITT was 64.3 weeks [21]. Greater than 25% increase in tumor
volume as compared to the immediate post-operative scan (after 24 h) was defined as local
treatment failure or recurrence. Mean tumor size that was treated using LITT was 3.66 cm3
and 3.3 lesions were treated per treatment [21]. Mean procedure time, mean duration of
ablation and in-patient hospital stay were 136.0, 7.43 and 1.2 days, respectively, in this study.
Interestingly, postoperative MRI (within 24 h) revealed an average increase of 278% in tumor
volume size following LITT in 12/14 patients and the other two patients showed 74 and 91%
decrease in preoperative tumor volume. Subsequently, greater than 10% reduction in tumor
volume was observed in seven patients at a median interval of 24 weeks, achieving a local
control rate of 75.8% (13 of 15 lesions). Two patients experienced recurrence at 4 and 18 weeks
following LITT within the treated zone and underwent surgical resection of the recurrent
tumor. The median progression-free survival and overall survival at 39 weeks follow up
were 37 weeks and 57%, respectively. Mortality was related to extra cranial disease in five
patients and intracranial disease distant from the treated site in one patient. Two complica‐
tions including non-operative hemorrhage (n = 1) and new onset hemiparesis (n = 1) was noted
following LITT; former patient expired secondary to extra cranial progression and the other
patient improved with steroids [21].
A recent study reported delayed failure in two patients who underwent LITT following tumor
progression and refractory cerebral edema after SRS [23, 49]. LITT was performed 7 months
(breast adenocarcinoma) and 14 weeks (lung adenocarcinoma) after stereotactic radiosur‐
gery. Patient with lung adenocarcinoma metastasis to the external capsule had significant
perilesional edema following radiosurgery and also experienced severe side effects secon‐
dary to steroid therapy (refractory hyperglycemia, weight gain and bilateral proximal muscle
weakness), therefore LITT was considered 14 weeks after SRS [23]. This patient had signifi‐
cant clinical improvement and steroid was weaned off in 2 weeks following ablation therapy.
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However, first patient with parietal metastasis and second patient with external capsule
metastasis demonstrated tumor recurrence at 6 and 11 months, respectively, which was
histologically confirmed following surgical resection [49]. A recent review based on pooled 25
patients with brain metastasis who were treated with LITT reported a median overall
survival (OS) of 12.6 months (range 9.0–19.8 months) and progression-free survival (PFS) to
vary between 3.8–8.5 months [127]. Severe complication rate was reported to be 8% and
included events such as perioperative hemorrhage (non-surgical) and blood suffusion.
Intracranial progression of disease (excluding local progression, 8%) and extra cranial
progression as the etiology of mortality was reported in 36 and 55% of patients respectively
following LITT for brain metastasis. Median survival time (9.0–19.8 months) and severe
complication rate of 8% following LITT are similar to 1.4–16.1 months and 6–19%, respective‐
ly, following surgical management of brain metastasis [128]. Given these comparable out‐
comes, LITT is an effective therapeutic option for patients with resistant brain metastasis in
difficult-to-access areas. There is a paucity of literature on the utility of LITT in patients with
radiation necrosis (RN). It is often difficult to distinguish patients with radiation necrosis and
those with tumor recurrence following stereotactic radiosurgery. Therefore, the majority of
reported cases could represent a mixture of these clinical conditions, even following stereo‐
tactic biopsy. In an anecdotal report, LITT was used for diagnosed RN following stereotactic
biopsy (may represent a mixed lesion), as patient was refractory and not able to tolerate
standard medical management (steroids and bevacizumab) for suspected RN [24]. Patient
developed several steroid-related complications along with several medical comorbidities. In
light of these facts and the presence of a lesion in a difficult-to-access area (left centrum
semiovale), LITT was considered in this patient with RN following SRS for brain metastasis
(non-small cell lung carcinoma). As demonstrated in earlier reports, there was a significant
improvement in clinical symptoms following LITT and patient was weaned off the steroid in 2
weeks after the procedure. However, there was a mild increase in size of lesion with no
significant FLAIR signal changes at 7 weeks postoperative MRI, which was consistent with the
literature.
Patel et al. [98] reported the utility of LITT in patients with a variety of intracranial patholo‐
gies including patients with recurrent metastasis or radiation necrosis (n = 37) [98]. Total
operative time and ablation time were 2.8±0.6 h and 8.7±8.1 mins, respectively. Postopera‐
tive complications such as neurological worsening (n = 7), hemorrhage (n = 1), edema (n = 1),
infection (n = 1) and thermal injury to pituitary leading to secondary complications (n = 1) were
reported [98]. Overall survival and progression-free survival or recurrence was not reported
in this study [98].
LITT has shown initial promising results in patients with recurrent brain metastasis and RN
(to some extent) following SRS. However, long-term prospective randomized controlled
studies are warranted and required to validate the efficacy of LITT for these clinical indications.
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8. Use of LITT in other intracranial tumors
Jethwa et al. [63] reported the application of Visualase laser system in 20 patients (33 proce‐
dures) with a variety of intracranial tumors over a period of 1 year. GBM was the most common
pathology treated (n = 6), followed by metastasis (n = 4), ependymoma (n = 3), meningioma
(n = 2), hemangioblastoma (n = 2), anaplastic astrocytoma (n = 1), chordoma (n = 1) and
supratentotrial primitive neuroectodermal tumor (n = 1) in this study. LITT was considered
primarily in patients with failed prior treatment (10 out of 20), in surgically inaccessible areas (n
= 3), patient preference (n = 3) or in those in who conventional surgery was considered high
risk (n = 4) [63]. Majority of patients were treated with single laser application; however, two
patients with GBM, one each with metastasis, meningioma, ependymoma underwent two
applications and one patient with GBM required three laser applications to cover the tumor
volume. One patient each with ependymoma and GBM underwent staged LITT procedure 2
months apart and one with supratentotrial primitive neuroectodermal tumor underwent
repeat procedure due to tumor recurrence. The average tumor volume and average tumor
diameter treated was 7.0± 9.0 cm3 and 2.4± 0.85 cm. The average ablation time was 13.9± 10.7
min and median hospital stay of 24 h (average stay of 2.27 days) in this study [63]. It was noted
in the study that LITT was well tolerated in the majority of patients with four procedure-related
complications. Inaccurate placement of laser probe (patient with cerebellum hemangioblasto‐
ma), placement-related hemorrhage (near right sylvian fissure meningioma), pituitary thermal
injury (pediatric patient with third ventricle recurrent ependymoma) and significant peripro‐
cedural edema (patient with GBM) were reported following 33 LITT procedures in 20 patients.
All these complications except pituitary thermal injury required open surgical procedure.
Tumor control rates and follow-up imaging were not reported in this study. Another group
reported the use of LITT in six patients with intracranial tumors (metastasis, n = 4; pituitary
prolactinoma, n = 1; medullary ependymoma) and one patient with conus ependymoma [129].
Complete ablation was achieved in six out of seven patients and no procedure-related adverse
effects were noted in these patients [129]. No long-term outcomes and follow-up results were
reported following LITT for these tumors. Recently, Patel et al. [98] reported the utility of LITT
using Visualase system in patients with a variety of intracranial tumors such as meningioma
(n = 2), ependymoma (n = 3), hemangioblastoma (n = 2), primitive neuroectodermal tumor (n
= 3), cavernoma (n = 2), chordoma (n = 1), teratoma (n = 1), CNS lymphoma (n = 1) and pineal
tumor (n = 1) [98]. Total operative time and ablation time were 2.8±0.6 hrs and 8.7±8.1 mins,
respectively, in all patients with intracranial tumors including glial tumors (GBM, ganglio‐
glioma, pilocytic astrocytoma). Postoperative complications such as neurological worsening
(n = 7), hemorrhage (n = 2), edema (n = 4), infection (n = 1), inaccurate catheter placement (n =
2) and two deaths following LITT were reported [98]. A major limitation of this study was that
outcomes including tumor control rates and recurrence were not reported in this study [98].
The procedure was not completed in two patients, one with recurrent meningioma due to
hemorrhage during probe insertion which required emergent evacuation and the second
patient with hemangioblastoma had inaccurate placement of laser probe which led to abortion
of the procedure.
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9. Use of LITT in cancer-related pain
Cancer-related pain is a significant clinical problem affecting up to 60–90% of patients with
cancer in terminal stages [130]. The first line of management in such patients is pharmacolog‐
ical including opioids; however, 10–20% of such patients are refractory to medical line of
management and thus requires intervention for pain management [131–133]. Various
neuromodulation and ablative procedures such as intrathecal morphine, myelotomy,
cordotomy, DREZotomy, sympathetic blocks, paravertebral blocks and cingulotomy have
been described for pharmacological-resistant, cancer-related and various refractory pain
syndromes [131–137]. Ablative cingulotomy using radiofrequency [136] and neuromodula‐
tion using DBS [138] has been described in patients with various refractory pain syndromes.
With the advances in neuroimaging and stereotactic techniques and introduction of LITT, this
technique has been explored in patients with pharmacoresistant cancer-related pain [12, 98].
Patel et al. [12] describe the feasibility of MRgLITT in three patients (four procedures) with
cancer-related pain. Ablation coordinates used in patients who underwent first-time abla‐
tion includes x = 7.9 mm (6.9–8.6mm range); y = 20.5 mm (20–22 mm range); Z = 6.9 mm (2.9–
7.0 mm) above the lateral ventricles. Second ablation 1–2 cm above the first ablation was
performed in patients with first-time ablation procedures. One patient who underwent
ablation for recurrence had three ablations. Median ablation time and volume ablated were
257 seconds and 1.5 cm3, respectively. Median pain severity score (PSS) decreased from 7.7 in
preoperative period to 1.6 following the LITT procedure. Similarly, pain interference score
(PIS) decreased from 9.9 to 2.0 following the procedure [12]. Median pain reduction was
maintained for 5 weeks (2–16 weeks) following LITT and all patients had significant reduc‐
tion in medication requirements during the period. No significant adverse effects related to
the procedure were noted in this study. The advantage of LITT is that the ablation can be
monitored in real-time using MR thermography, which was not feasible in earlier ablative
techniques.
Another recent study reported the utility of LITT in five patients with chronic pain syn‐
drome [98]. Total operative time and ablation time were 2.9±0.3 h and 4.3±0.6 mins, respec‐
tively. No postoperative complications were noted following LITT in patients with chronic
pain [98]. Outcomes in terms of pain control was not reported in this study [98].
10. Use of LITT in epilepsy
Pharmacoresistant or drug-resistant epilepsy (DRE) is a significant clinical challenge with
prevalence of approximately 28 to 40% in patients with epilepsy [139, 140]. In addition,
approximately 10% of pediatric patients with epilepsy meet the criterion of DRE within 18
months of diagnosis [140]. Epilepsy surgery has been shown to have beneficial long-term
effects in terms of seizure control (seizure free outcome rate of 67 and 26% at 5 and 15 years
follow-up, respectively) and psychosocial outcomes in patients with DRE [141–143]. Based on
a recent meta-analysis, the incidence of neurological deficits, permanent neurological deficits,
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wound infection/meningitis following temporal lobectomy with/without amygdalohippo‐
campectomy and extratemporal lobar/multilobar resections have been reported to be 5.2, 0.8,
1.1 and 19.5, 3.2, 1.9%, respectively [144]. The complication rates have been shown to in‐
crease from 10% during first resective surgery in pediatric patients with complex refractory
epilepsy to 50% during second respective surgery [145]. Given this success of epilepsy surgery
in controlling seizures with associated morbidity in patients with DRE, there is always a need
to improvise on surgical techniques so as to reduce the morbidity while improving the
outcomes. Introduction of MRI-guided LITT in neurosurgery over the past decades have paved
a way to exploration of this technique in patients with DRE. MRgLITT is a minimally invasive
stereotactic technique that can be used to ablate the epileptogenic zone and associate fibers so
as to simulate the resection and disconnection procedures, respectively. FDA approved Auto
LITT in 2009, following a successful Phase 1 multicenter trial investigating the safety of this
system in patients with recurrent GBM. In 2012, Curry et al. [146] first reported the use of MRI-
guided (1.5T) LITT (Visualase thermal system) in five patents with DRE. In this study, they
ablated six epileptic zones (cingulate tuber n = 1, mesial temporal sclerosis n = 1, hypothala‐
mic hamartoma n = 2 and frontal cortical dysplasia n = 2) in five patients with DRE and all
patients were reported to be seizure-free at 2–13 months of follow up [146]. No complica‐
tions were reported in this study. Another study reported the use of this modality in a 3-year-
old with a diagnosis of precocious puberty and pharmacoresistant gelastic seizures and MRI
showed type III hypothalamic hamartoma (both pedunculated and sessile component) [88].
Patient underwent MRgLITT using Visualase system without perioperative complications.
There was significant improvement in behavior and seizures at 2 weeks after the procedure.
At 6 months follow up, patient remained seizure-free with improvement in behavior and self-
indulging learning patterns such as playing and entertainment [88]. A year later, Wellmer et
al. [147] reported the successful use of 3T MR-guided stereotactic radiofrequency thermal
coagulation in two patients with DRE due to type IIB frontal focal cortical dysplasia. These
focal cortical dysplasias were identified as epileptogenic zones prior to LITT and one of these
lesions was in close proximity to the cortico-spinal tract as elicited by the motor-evoked
potentials using in-depth electrodes. Both patients were seizure-free at 12 and 5 months with
no persistent postoperative complications (one patient had transient mouth paresis) follow‐
ing thermal coagulation [147]. Authors emphasized the importance of precise placement of
radiofrequency probe and destruction of epileptogenic zone, taking into account the sur‐
rounding eloquent area. Gonzalez-Martinez et al. [148] reported robot (ROSA, Medtech
Surgical, Inc.) assisted placement of laser probe (Visualase Inc.) under intraoperative MRI
guidance to ablate a periventricular heterotopic lesion in a 19-year-old female with DRE of 10-
years duration. Authors reported that combination of robot, LITT and intraoperative MRI is a
safe, accurate, efficacious and time-efficient minimally invasive technique that can be used for
placement and ablation of epileptogenic zone in patients with DRE [148]. Esquenazi and
colleagues [149] reported the utility and feasibility of stereotactic MRgLITT (3T) in two patients
with DRE and periventricular nodular heterotopia. One patient underwent temporal lobecto‐
my in addition to LITT and was seizure-free during the follow up and another patient had
significant seizure control leading to adjustment in medications following the procedure [149].
Former patient with two procedures had transient visual deficit and no complications in
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another patient were reported during the follow up. Stereotactic placement of multiple
trajectories to achieve conformity of complex tumor shapes at deeper locations was also
described in this report. Recently, Lewis and colleagues [150] described the feasibility and
efficacy of MRgLITT in 17 pediatric patients with DRE using Visualase system. In this
retrospective study, 17 patients with DRE underwent 19 MRgLITT procedures with a mean
follow up of 16.1 months. Focal cortical dysplasia (n = 12) was the most common pathology
followed by tuberous sclerosis complex (n = 5), hypothalamic hamartoma (n = 1), mesial
temporal sclerosis (n = 1), Rasmussen encephalitis (n = 1) and tumor (n = 1) [150]. One LITT
procedure was aborted and one was partially completed leading to completion of LITT in 17
procedures. Nine patients had prior surgeries including two patients had three, one had two
and the rest had one procedure each prior to LITT. Engel class I, class II, class III and class IV
outcome were achieved in 41, 6, 18 and 35%, respectively, following LITT with an average
postprocedure hospital stay of 1.56 days. 38% of patients with Engel class I/II outcomes and
56% of patients with Engel class III/IV outcomes had at least one resective surgery prior to
LITT [150]. Inaccurate fiber placement, device malfunction, inaccurate fiber placement with
IVH (aseptic meningitis and ventriculostomy) and post-ablation edema/drug-induced gastritis
were noted in one patient each leading to eight individual complications in four patients [150].
Patients with lesions <2 cm in size, well-circumscribed solitary lesions and concordant EEG
and presurgical data were considered optimal candidates for LITT ablation in this study [150].
Recently, Patel et al. [98] reported the utility of LITT in 10 patients with pharmacoresistant
epilepsy [98]. Total operative time and ablation time were 2.6±0.4 h and 7.6±2.3 mins, respec‐
tively. No procedure-related complications were noted in this study. However outcome in
terms of seizures control was not reported in this study [98]. Based on these studies, LITT has
shown promising results in patients with DRE, especially those who require repeat resection
surgery with favorable outcome while minimizing morbidity. However, long-term prospec‐
tive randomized controlled studies are warranted to validate the efficacy of LITT in patients
with DRE and to establish appropriate selection and inclusion criterion to achieve favorable
outcomes.
11. Future trends
FDA approved AutoLITT in 2009, following a multicenter trial investigating the efficacy of
this modality in patients with recurrent GBM. Laser ablation has currently been investigated
as a potential treatment modality in patients with failed stereotactic radiosurgery for brain
metastasis (NCT01651078, Laser Ablation after Stereotactic Radiosurgery, LAASR study).
Following these results, LITT is likely to be explored in other areas of neuro-oncology.
12. Our experience
At Cleveland clinic we have an experience of about 150 patients, who underwent LITT for a
variety of indications since 2011. At our center, we use NeuroBlate® System (Monteris Medical
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Corporation, Plymouth, MN, USA) with a side firing probes (Figure 1). Regarding intra-axial
tumors, we have used LITT in 30 patients with de novo GBM, 24 patients with recurrent
GBM (following standard treatment), 22 patients with recurrent anaplastic tumors, upfront
in 10 patients with anaplastic tumors, 24 patients with low-grade gliomas (7 upfront and 17
recurrent). We have also used this modality in 17 patients with radiation necrosis and 15
patients with metastasis. We are also participating in a multi-institutional study investigat‐
ing the role of this modality in patients with failed SRS (LAASR study). We have also utilized
this therapy in patients with recurrent meningioma (n = 4) and schwanomma (n = 1, upfront)
as well as epilepsy surgery (more than five cases).
13. Conclusion
LITT is a stereotactic minimally invasive technique that involves ablation of pathological tissue
using laser energy. This technique has shown promising results in a variety of neuro-onco‐
logical conditions such as recurrent GBM, upfront deep-seated GBM, recurrent metastasis
following SRS, radiation necrosis and cancer-related pain. LITT was approved by FDA in 2009
for unlimited intracranial usage. Minimally invasive nature of the therapy coupled with real-
time monitoring of thermal ablation are distinct advantages of LITT over traditional surgical
approaches, especially for deep-seated tumors in patients with significant co-morbidities.
Currently, there is Level III /Level IV evidence in the literature supporting the role of LITT in
patients with recurrent GBM/high-grade gliomas, metastasis and radiation necrosis. There is
a paucity of data regarding other indications of LITT. However, trials are underway and are
likely to provide significant level of evidence supporting the efficacy of LITT in a variety of
the above-mentioned indications in coming years.
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